PT  - JOURNAL ARTICLE
AU  - Agrawal, Disha
AU  - Shrinivas, Divya
AU  - Sharma, Parth
AU  - Rajagopal, M R
AU  - Ghoshal, Arun
AU  - Zadey, Siddhesh
TI  - An evaluation of the adequacy of Indian national and state Essential Medicines Lists (EMLs) for palliative care medical needs - a comparative analysis
AID  - 10.1101/2024.08.26.24312600
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.08.26.24312600
4099  - http://medrxiv.org/content/early/2024/08/28/2024.08.26.24312600.short
4100  - http://medrxiv.org/content/early/2024/08/28/2024.08.26.24312600.full
AB  - Objectives Essential Medicines Lists (EMLs) guide the public sector procurement and supply of medications to impact access to adequate and appropriate palliative care drugs. This study evaluates the adequacy of India’s national and sub-national EMLs that can directly impact palliative care for 5.4 million patients.Methods In this qualitative document review, we compared Indian national, and state EMLs acquired from official government websites with the International Association for Hospice & Palliative Care (IAHPC) EML recommendations. We analysed data on the indication and formulation of drugs under the different categories of formulations present (all, some, and no), and drugs absent. Literature review and inputs from palliative care experts provided alternatives of absent medications to assess the adequacy of lists in managing the symptoms listed by IAPHC.Results We analysed 3 national and 25 state lists for 33 recommended drugs. The Central Government Health Services list had the maximum availability of all formulations of drugs (16 [48%]) nationally. Among states and union territories, the Delhi EML was the closest to IAHPC with 17 (52%) drugs with all formulations present. Nagaland had the most incomplete EML with only 3 (9%) drugs with all formulations present. No EML had all the recommended formulations of morphine. In one national and sixteen state EMLs, oral morphine was absent.Conclusion While Indian EMLs lack drugs for palliative care when compared with the IAHPC EML, symptom management is adequate. There is a need for countries with limited resources to modify the IAPHC list for their settings.What is already known on this topic Essential Medicines Lists (EMLs) are instrumental in guiding public sector procurement of drugs. The implementation of EMLs is known to improve drug availability and prescription practices. The rising burden of people requiring end-of-life care globally necessitates the availability of appropriate drugs for the medical management of symptoms, which can be achieved through their inclusion in local EMLs.What this study adds The national and sub-national EMLs of India do not fully adhere to the International Association for Hospice and Palliative Care (IAHPC) recommendations. However, they contain adequate drugs for the management of the listed symptoms. Additionally, the inclusion of various formulations of morphine remains a challenge to be addressed.How this study might affect research, practice or policy This study highlights the need to develop a fit-for-purpose EML for palliative care, taking into account the geographical variations in palliative care needs, and resource constraints in healthcare delivery at the state and country level.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNilAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available upon reasonable request